This webcast is not certified for credit

Release Date: September 15, 2021
Expiration Date: September 14, 2022

Activity Overview
This webcast will provide expert interpretation of emerging data and guidance regarding current and emerging therapies for the treatment of patients with various aggressive and indolent lymphoma subtypes.

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma.

Learning Objectives
After participating in this activity, participants should be better able to:

• Assess current and emerging approaches to the treatment of patients with aggressive B-cell lymphoma, and optimal patient management strategies
• Evaluate clinical trial data of both approved and novel agents and regimens being investigated in patients with indolent lymphoma
• Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma   

Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Physician Leader, Lymphoma Critical Care Program
Stanford Cancer Institute
Palo Alto, California

Andrew Zelenetz, MD, PhD
Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medicine
New York, New York

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:   

Faculty 
Matthew A. Lunning, DO, FACP
Acrotech Biopharma (Self) : Consulting (Status: Ongoing); AstraZeneca/Acerta (Self) : Consultant (Status: Ongoing); Beigene (Self) : Consulting (Status: Ongoing); Bristol Myers Squibb (Self) : Consultant (Status: Ongoing); Bristol-Myers Squibb (Self) : Research Grant Support (Status: Ongoing); Celgene (Self) : Advisory Board (Status: Ongoing), Consulting (Status: Ongoing); Curis (Self) : Research grant support (Status: Ongoing); Daiichi Sankyo (Self) : Consulting (Status: Ongoing); Gilead Sciences (Self) : Consultant (Status: Ongoing); Janssen/Pharmacyclics (Self) : Consultant (Status: Ongoing); Karyopharm (Self) : Consulting (Status: Ongoing); Kite (Self) : Consultant (Status: Ongoing); Legend Pharmaceuticals (Self) : Consulting (Status: Ongoing); Morphosys (Self) : Consulting (Status: Ongoing); Myeloid Therapeutics (Self) : Consulting (Status: Ongoing); Spectrum (Self) : Consulting (Status: Ongoing); TG Therapeutics (Self) : Consultant (Status: Ongoing); Verastem (Self) : Consulting (Status: Ongoing)

Ranjana Advani, MD
Roche (Self): Advisory Board: (Status: Ongoing), Celgene: (Self); Advisory Board: (Status: Ongoing), Takeda: (Self); Advisory Board: (Status: Ongoing), Seattle Genetics: (Self); Advisory Board: (Status Ongoing), Epizyme (Self); Advisory Board: (Status: Ongoing), Sanofi (Self); Advisory Board: (Status: Ongoing), Kura (Self); Advisory Board: (Status: Ongoing), ADCT: (Self); Advisory Board: (Status: Ongoing), Karyopharm; (Self); Advisory Board: (Status: Ongoing); Merck: (Self); Advisory Board: (Status: Ongoing), BMS: (Self); Advisory Board: (Status: Ongoing), Daichi Sanyo: (Self): Advisory Board: (Status: Ongoing); Incyte: (Self); Advisory Board: (Status: Ongoing)

Seattle Genetics: (Self); Institutional research funding (Status: Ongoing), Regeneron: (Self); Institutional research funding: (Status: Ongoing); Pharmacyclics: (Self); Institutional research funding: (Status: Ongoing), Merck: (Self); Institutional research funding: (Status: Ongoing); Forty-Seven: (Self): Institutional research funding: (Status: Ongoing);  Cyteir: (Self); Institutional research funding: (Status: Ongoing); Millennium: (Self); Institutional research funding; (Status: Ongoing); ADCT: (Self); Institutional research funding: (Status: Ongoing);  Kura: (Self); Institutional research funding: (Status: Ongoing)

Andrew D. Zelentz, MD. PhD
AbbVie (Self) : Consultant (Status: Ongoing); Adaptive Biotechnology (Self) : Consultant (Status: Ongoing); Amgen (Self) : Consultant (Status: Ongoing); Astra Zeneca (Self) : Consultant (Status: Ongoing); Beigene (Self) : DMC Chair (Status: Ongoing), Research (Status: Ongoing); Bristol Myers Squibb (Self) : DMC Member (Status: Ongoing); Celgene (Self) : Consultant (Status: Ongoing), DMC Member (Status: Ongoing); Gilead (Self) : Consultant (Status: Ongoing), Research (Status: Ongoing); Janssen (Self) : Consultant (Status: Ongoing); Juno (Self) : DMC Member (Status: Ongoing); Mei Pharma (Self) : Consultant (Status: Ongoing), Research (Status: Ongoing); Morphosys (Self) : Consultant (Status: Ongoing); Novartis (Self) : Consultant (Status: Ongoing); Roche (Self) : Research (Status: Ongoing); Roche/Genentech (Self) : Consultant (Status: Ongoing)

Planning Committee​
The following planning committee members have nothing to disclose:​
UNMC: Brenda Ram, CMP, CHCP​; Valeta Creason-Wahl, HMCC; Renee Paulin, MSN, RN, CWOCN
Bio Ascend: Chloe Dunnam; Dru Dace, PhD; Kraig Steubing

Support
This activity is supported by educational grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, Incyte Corporation, MorphoSys, and TG Therapeutics, Inc.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.